Visby Medical today announced the national launch of what it's calling a first-of-its-kind FDA-authorized at-home PCR test for sexually transmitted infections (STIs) in women.
The palm-sized test, now available nationwide with virtual care support and home delivery, detects three of the most common and often asymptomatic infections—chlamydia, gonorrhea, and trichomoniasis—in 30 minutes.
Google Cloud is supporting Visby’s vision with secure, scalable, and AI-ready infrastructure for its digital platform. This partnership ensures users can transition from receiving test results to accessing medical care through Optum Now, and positions Visby’s platform to integrate future AI-driven healthcare solutions.
To enhance accessibility, convenience, and discretion, the product is available for on-demand delivery via instant-commerce leader Gopuff, which powers deliveries placed on Visby.com straight to customers’ doors, and leading local commerce platform DoorDash. This enables discrete, immediate home delivery in 10 major metropolitan areas—including the San Francisco Bay Area, Las Vegas, and New York—with ongoing expansion planned for additional regions in the near future.
Available now on Everlywell.com, the test expands private, self-directed access to millions of consumers through Everlywell’s established diagnostics platform.
“STI testing still carries significant barriers—stigma, access, and time,” said Julia Cheek, Founder and CEO of Everlywell. “We're breaking those down by launching Visby’s revolutionary device on Everlywell.com, empowering individuals to easily and confidently manage their sexual health at home.”
Visby will continue to build on Google Cloud’s Vertex AI platform with Gemini-based functionality. Over the next year, AI-driven guidance will be integrated into the user interface, providing personalized patient education and wellness advice. This could include proactive tips for sexual health, reminders for follow-up testing, and other general wellness information tailored to each user's profile.
In addition, Visby Medical continues to innovate with upcoming products including a men’s Sexual Health test, a sore throat panel detecting strep and common viruses, and a urinary tract infection test with antibiotic resistance detection capability.
The Visby Women’s Sexual Health PCR test is available for $149.99. Users swab themselves, insert the sample into the device, and receive results within 30 minutes through a mobile app developed on Google Cloud and available for download at all major mobile app stores. The test is an eligible expense for both FSA and HSA accounts.
